1.Beck, J. R., Kassirer, J. P., & Pauker, S. G.A convenient approximation of life expectancy; The “DEALE.” American Journal of Medicine, 1982, 73, 863–97.
2.Drummond, M. F., Stoddart, G. L., & Torrance, G. W.Methods for the economic evaluation of health care programmes. Oxford, U.K.: Oxford University Press, 1987.
3.Johannesson, M., & Jönsson, B. Cost-effectiveness analysis of hypertension treatment — Methodological issues. CMT Report, Linköping, Sweden: Linköping University Center for Medical Technology Assessment, 1990, 5.
4.Keeler, E., & Cretin, S.Discounting of life savings and other non-monetary effects. Management Science, 1983, 29, 300–06.
5.Martens, L., & Van Doorslaer, E.Dealing with discounting: An application to the cost-effectiveness of intracoronary thrombolysis with streptokinase. International Journal of Technology Assessment in Health Care, 1990, 6, 139–45.
6.Rosen, S.The value of changes in life expectancy. Journal of Risk and Uncertainty, 1988, 1, 285–304.
7.Vermeer, F., Simoons, M. L., de Swaan, C., et al. Cost-benefit analysis of early thrombolytic treatment with intracoronary streptokinase. British Heart Journal, 1988, 59, 527–34.
8.Weinstein, M. C., & Stason, W. B.Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine, 1977, 296, 716–21.